Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 0.00% is 100% below its 5-year average of 0.50%, near the high end of its 5-year range (-17476.92%–7106.55%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
5.24%
NET PROFIT MARGIN AVG 5Y
0.50%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
-100.00%
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 561 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Amylyx Pharmaceuticals, Inc.
Market Cap
$3.01B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
5.24%
5Y Avg
0.50%
Market Cap
$3.04B
Net Profit Margin
6.15%
TTM Avg
-37.77%
3Y Avg
-2241.27%
5Y Avg
-1494.18%
Market Cap
$3.09B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.05B
Net Profit Margin
-14191.20%
TTM Avg
0.00%
3Y Avg
-86.13%
5Y Avg
-153.41%
Market Cap
$2.80B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.83B
Net Profit Margin
22.69%
TTM Avg
19.73%
3Y Avg
-2.42%
5Y Avg
-44.65%
Market Cap
$2.81B
Net Profit Margin
1.85%
TTM Avg
-5.88%
3Y Avg
-8.36%
5Y Avg
-6.41%
Market Cap
$2.71B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.71B
Net Profit Margin
10.56%
TTM Avg
9.25%
3Y Avg
0.54%
5Y Avg
-8.48%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. (AMLX) | $3.01B | 0.00% | 0.00% | 5.24% | 0.50% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.04B | 6.15% | -37.77% | -2241.27% | -1494.18% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.09B | 0.00% | 0.00% | 0.00% | 0.00% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.05B | -14191.20% | 0.00% | -86.13% | -153.41% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.80B | 0.00% | 0.00% | 0.00% | 0.00% |
| TransMedics Group, Inc. (TMDX)vs › | $2.83B | 22.69% | 19.73% | -2.42% | -44.65% |
| AtriCure, Inc. (ATRC)vs › | $2.81B | 1.85% | -5.88% | -8.36% | -6.41% |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.71B | 0.00% | 0.00% | 0.00% | 0.00% |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.71B | 10.56% | 9.25% | 0.54% | -8.48% |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.67B | -33.44% | -12.59% | -3.87% | -6.56% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 5646.02% |
| 2024-09-30 | -17476.92% |
| 2024-06-30 | 7106.55% |
| 2024-03-31 | -134.01% |
| 2023-12-31 | 4.36% |
| 2023-09-30 | 20.35% |
| 2023-06-30 | 22.47% |
| 2023-03-31 | 2.20% |
| 2022-12-31 | -195.13% |
| 2022-09-30 | -15581.45% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
